Abstract:
A compound is selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof.
Abstract:
A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
Abstract:
The present invention relates to compounds of following formula (I) useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders, such as cancer.
Abstract:
The present invention relates to compounds of formula I useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative disorders. Formula (I).
Abstract:
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders. Formula (I) where Q is C1-6 alkylidene chain wherein one methylene unit of Q is replaced by -C(O)N(R)-, -C(O)-, -C(O)O-, -N(R)-, -O-, -S-, -SO2-, or -SO2N(R)-; each R is independently hydrogen or an optionally substituted C1-6 aliphatic group, wherein: two R groups on the same nitrogen atom are optionally taken together with said nitrogen atom to form an optionally substituted 3-7 membered saturated, partially unsaturated, of fully unsaturated ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R is H, -N(R)2, or an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 5-6 membered aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-10 membered bicyclic partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R is an optionally substituted 6-membered aryl ring having 0-3 nitrogens; R is R, CN, NO2, halogen, N(R)2, OR, or SR; and Ring A is an optionally substituted ring selected from formulas (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o) or (p).
Abstract translation:本发明涉及可用于蛋白激酶抑制剂的化合物。 本发明还提供了制备本发明化合物的方法,包含本发明化合物的药学上可接受的组合物,以及使用该组合物治疗各种疾病的方法。 式(I)其中Q是C 1-6亚烷基链,其中Q的一个亚甲基单元被-C(O)N(R) - , - C(O) - , - C(O) (R) - , - O - , - S - , - SO 2 - 或-SO 2 N(R) - ; 每个R独立地为氢或任选取代的C 1-6脂族基团,其中:相同氮原子上的两个R基团任选与所述氮原子一起形成任选取代的3-7元饱和,部分不饱和的完全不饱和的 具有1-3个独立地选自氮,氧或硫的杂原子的环; R 1是H,-N(R)2或任选取代的环,其选自具有0-3个独立地选自氮,氧或硫的杂原子的3-7元饱和或部分不饱和的环; 具有0-4个独立地选自氮,氧或硫的杂原子的5-6元芳环; 或具有0-4个独立地选自氮,氧或硫的杂原子的8-10元双环部分不饱和或芳环; R 2是具有0-3个氮的任选取代的6元芳环; R 3是R,CN,NO 2,卤素,N(R)2,OR或SR; 环A是选自式(a),(b),(c),(d),(e),(f),(g),(h),(i),(j) ,(k),(l),(m),(n),(o)或(p)。
Abstract:
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
Abstract:
The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
Abstract:
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
Abstract:
This invention describes novel triazole compounds of formula (IX): wherein Z is nitrogen or CR and Z is nitrogen or CH, provided that at least one of Z and Z is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R ; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R and R are independently selected from T-R , or R and R are taken together with their intervening atoms to form a fused ring; R , R , and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.